CHST1 as a prognostic-related biomarker in gastric cancer correlating with immune infiltration.
Carbohydrate sulfotransferase (CHST) is a Golgi membrane-associated enzyme with potential as a cancer diagnostic marker.
APA
Gui L, Yu JH, et al. (2025). CHST1 as a prognostic-related biomarker in gastric cancer correlating with immune infiltration.. Heliyon, 11(3), e42124. https://doi.org/10.1016/j.heliyon.2025.e42124
MLA
Gui L, et al.. "CHST1 as a prognostic-related biomarker in gastric cancer correlating with immune infiltration.." Heliyon, vol. 11, no. 3, 2025, pp. e42124.
PMID
39944327
Abstract
Carbohydrate sulfotransferase (CHST) is a Golgi membrane-associated enzyme with potential as a cancer diagnostic marker. In this study, we obtained the transcriptional profile and corresponding clinical information of CHST1 in gastric cancer (GC) tissues and normal tissues from The Cancer Genome Atlas database. Our functional experiments have demonstrated that CHST1 enhances the proliferation and metastasis of GC cells, both and . Furthermore, we constructed a co-expression network of CHST1 and explored its relationship with clinicopathological features, the tumor microenvironment, and immune infiltration through bioinformatics analysis. Finally, relevant drugs that inhibit CHST1 in GC were predicted using the drug susceptibility database (CellMiner) and Cancer Immunome Atlas. Overall, CHST1 may serve as a promising prognostic biomarker for GC, as it is linked to immune infiltration and facilitates GC cell proliferation and metastasis.
같은 제1저자의 인용 많은 논문 (5)
- Securinine bolsters anti-tumor immunity by promoting CD8⁺ T cell activation.
- Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.
- Gossypol suppresses tumorigenesis through inhibition of multiple deubiquitinating enzymes.
- Case report: Complete response of an anaplastic thyroid carcinoma patient with Q61R/ D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody.
- Genioplasty and chin augmentation with Medpore implants: a report of 650 cases.